Approaches to target cellular effectors of BCR-ABL may provide a complementary/enhancing approach to the use of TKIs and/or help overcome resistance in cases of resistant CML or Ph+ ALL. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.